Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shenbai Granules for Preventing High-Risk Colorectal Adenomas
NCT07129499Not yet recruiting
- Sponsor
- Jiangsu Famous Medical Technology
- Start
- Aug 2025
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in Colorectal Adenoma (CRA) comparing Shenbai Granules with Placebo (2 arms). Primary endpoint: Cumulative detection rate of metachronous high-risk colorectal adenomas at 3 years. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
Shenbai Granules
03
Conditions
Colorectal Adenoma (CRA)
Beyond the preview
Go deeper on NCT07129499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07129499.